Compare Abeona Therapeutics Inc (ABEO) vs Micron Technology, Inc. (MU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Micron Technology, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Micron Technology, Inc. trades at $942.26 (market cap $1.06T). The key difference: Micron Technology, Inc. is far larger — about 2839.4× Abeona Therapeutics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MU | |
|---|---|---|
Market Cap | $373.32M | $1.06T |
Sector | Health | Technology |
52-Week High | $7.23 | $1.21K |
52-Week Low | $4.17 | $104.88 |
Enterprise Value | $228.22M | $1.04T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Micron Technology (MU) trades at $938.38, down 3.81% amid a sector-wide chip stock selloff, despite strong fundamentals including a 22.84% net margin and three consecutive quarterly earnings beats. The stock shows a bullish technical trend with support near $933, while analyst consensus remains strongly positive with a $1,540 price target. Recent news highlights AI-driven demand and new supply deals with Ford and GM, though competition and cyclicality pose risks.
Outlook is positive given robust earnings growth and AI memory demand, but investors face volatility from memory market cycles and competitive pressures. The stock offers upside to analyst targets if execution continues, yet macroeconomic and sector rotations could drive near-term swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
